Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer.

摘要: To grow and metastasize, solid tumours must develop their own blood supply by neo-angiogenesis. Thalidomide inhibits the processing of mRNA encoding peptide molecules including tumour necrosis factor-alpha (TNF-α) angiogenic factor vascular endothelial growth (VEGF). This study investigated use continuous low dose in patients with a variety advanced malignancies. Sixty-six (37 women 29 men; median age, 48 years; range 33–62 years) measurable cancer (19 ovarian, 18 renal, 17 melanoma, 12 breast cancer) received 100 mg orally every night until disease progression or unacceptable toxicity was encountered. Three renal showed partial responses further three experienced stabilization for up to 6 months. Although no objective were seen other types, there significant improvements patients’ sleeping (P< 0.05) maintained appetite 0.05). Serum urine concentrations basic fibroblast (bFGF), TNF-α VEGF measured during treatment higher levels associated progressive disease. well tolerated: Two developed WHO Grade 2 peripheral neuropathy eight grade lethargy. No 3 4 toxicity. Further studies evaluating at doses as single agent combination biochemotherapy regimens are warranted. © 2000 Cancer Research Campaign